CXCR1 and neoplasm: According to the expression levels of CXCL8 and/or its receptors in the serum, tumor tissue, and CTCs, as well as other clinical parameters, we may develop monotherapy or even combination therapies based on therapeutic strategies targeting CXCL8-CXCR1/2 signaling and other therapies such as immunotherapy to achieve successful treatment.